-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NCNcsGd3XUG+qfEQw5ltX2WPl6SGiTzdJJ+WxX1r7g5GIPvHlPrxBjnt4QVK0E6i bTA+AIFz3lnlzojYrjkZjA== 0001144204-08-051235.txt : 20080904 0001144204-08-051235.hdr.sgml : 20080904 20080904160035 ACCESSION NUMBER: 0001144204-08-051235 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080904 ITEM INFORMATION: Other Events FILED AS OF DATE: 20080904 DATE AS OF CHANGE: 20080904 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IMCLONE SYSTEMS INC CENTRAL INDEX KEY: 0000765258 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042834797 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19612 FILM NUMBER: 081056490 BUSINESS ADDRESS: STREET 1: 180 VARICK STREET - 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: 646-638-5078 MAIL ADDRESS: STREET 1: 180 VARICK STREET - 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: IMCLONE SYSTEMS INC/DE DATE OF NAME CHANGE: 19940211 8-K 1 v125626_8k.htm Unassociated Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 4, 2008

IMCLONE SYSTEMS INCORPORATED
(Exact name of registrant as specified in its charter)
 

Delaware
  
0-19612
  
04-2834797
(State or other jurisdiction of Incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)

180 Varick Street
New York, New York 10014
(Address of principal executive offices) (Zip Code)

(212) 645-1405
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 

Item 8.01 Other Events.

ImClone Systems Incorporated has received a clinical update from the Phase 3 CRYSTAL study of ERBITUX® (cetuximab) plus FOLFIRI, an irinotecan-based chemotherapy, in patients with previously untreated metastatic colorectal cancer (the "clinical update"). As reported in 2007, the 1,198-patient CRYSTAL study, conducted by Merck KGaA, Darmstadt, Germany, met its primary endpoint of increasing progression-free survival. The clinical update includes data on the secondary endpoint of overall survival. Full CRYSTAL study results, including the clinical update as well as additional efficacy and safety data in all patient populations, will be presented at the European Society of Medical Oncology Annual Meeting in Stockholm, Sweden, taking place September 12-16, 2008.

 
 
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
IMCLONE SYSTEMS INCORPORATED
(Registrant)
 
 
Dated: September 4, 2008
By:
/s/ Andrew K. W. Powell                                                
Andrew K. W. Powell
Senior Vice President and General Counsel

 
 
 
 
 -----END PRIVACY-ENHANCED MESSAGE-----